262 related articles for article (PubMed ID: 23806553)
1. Discovery of triazines as potent, selective and orally active PDE4 inhibitors.
Gewald R; Grunwald C; Egerland U
Bioorg Med Chem Lett; 2013 Aug; 23(15):4308-14. PubMed ID: 23806553
[TBL] [Abstract][Full Text] [Related]
2. Discovery of oral and inhaled PDE4 inhibitors.
Ting PC; Lee JF; Kuang R; Cao J; Gu D; Huang Y; Liu Z; Aslanian RG; Feng KI; Prelusky D; Lamca J; House A; Phillips JE; Wang P; Wu P; Lundell D; Chapman RW; Celly CS
Bioorg Med Chem Lett; 2013 Oct; 23(20):5528-32. PubMed ID: 24018187
[TBL] [Abstract][Full Text] [Related]
3. Discovery of potent, selective, bioavailable phosphodiesterase 2 (PDE2) inhibitors active in an osteoarthritis pain model, part I: transformation of selective pyrazolodiazepinone phosphodiesterase 4 (PDE4) inhibitors into selective PDE2 inhibitors.
Plummer MS; Cornicelli J; Roark H; Skalitzky DJ; Stankovic CJ; Bove S; Pandit J; Goodman A; Hicks J; Shahripour A; Beidler D; Lu XK; Sanchez B; Whitehead C; Sarver R; Braden T; Gowan R; Shen XQ; Welch K; Ogden A; Sadagopan N; Baum H; Miller H; Banotai C; Spessard C; Lightle S
Bioorg Med Chem Lett; 2013 Jun; 23(11):3438-42. PubMed ID: 23582272
[TBL] [Abstract][Full Text] [Related]
4. Identification of 2,3-disubstituted pyridines as potent, orally active PDE4 inhibitors.
Kato Y; Kawasaki M; Nigo T; Nakamura S; Fusano A; Teranishi Y; Ito MN; Sumiyoshi T
Bioorg Med Chem; 2013 Sep; 21(18):5851-4. PubMed ID: 23910988
[TBL] [Abstract][Full Text] [Related]
5. Design, synthesis and biological evaluation of novel tetrahydroisoquinoline derivatives as potential PDE4 inhibitors.
Song G; Zhao D; Hu D; Li Y; Jin H; Cui Z
Bioorg Med Chem Lett; 2015 Oct; 25(20):4610-4. PubMed ID: 26320621
[TBL] [Abstract][Full Text] [Related]
6. Discovery of oxazole-based PDE4 inhibitors with picomolar potency.
Kuang R; Shue HJ; Xiao L; Blythin DJ; Shih NY; Chen X; Gu D; Schwerdt J; Lin L; Ting PC; Cao J; Aslanian R; Piwinski JJ; Prelusky D; Wu P; Zhang J; Zhang X; Celly CS; Billah M; Wang P
Bioorg Med Chem Lett; 2012 Apr; 22(7):2594-7. PubMed ID: 22401864
[TBL] [Abstract][Full Text] [Related]
7. Synthesis, Anti-inflammatory Activity and Docking Studies of Some Newer 1,3-Thiazolidine-2,4-dione Derivatives as Dual Inhibitors of PDE4 and PDE7.
Sharma H; Lather V; Grewal AS; Pandita D
Curr Comput Aided Drug Des; 2019; 15(3):225-234. PubMed ID: 30280674
[TBL] [Abstract][Full Text] [Related]
8. Discovery of potent selective bioavailable phosphodiesterase 2 (PDE2) inhibitors active in an osteoarthritis pain model. Part II: optimization studies and demonstration of in vivo efficacy.
Plummer MS; Cornicelli J; Roark H; Skalitzky DJ; Stankovic CJ; Bove S; Pandit J; Goodman A; Hicks J; Shahripour A; Beidler D; Lu XK; Sanchez B; Whitehead C; Sarver R; Braden T; Gowan R; Shen XQ; Welch K; Ogden A; Sadagopan N; Baum H; Miller H; Banotai C; Spessard C; Lightle S
Bioorg Med Chem Lett; 2013 Jun; 23(11):3443-7. PubMed ID: 23597790
[TBL] [Abstract][Full Text] [Related]
9. Synthesis and biological activity of pyrido[3',2':4,5]furo[3,2-d]pyrimidine derivatives as novel and potent phosphodiesterase type 4 inhibitors.
Taltavull J; Serrat J; Gràcia J; Gavaldà A; Córdoba M; Calama E; Montero JL; Andrés M; Miralpeix M; Vilella D; Hernández B; Beleta J; Ryder H; Pagès L
Eur J Med Chem; 2011 Oct; 46(10):4946-56. PubMed ID: 21871695
[TBL] [Abstract][Full Text] [Related]
10. Pharmacology of a potent and selective inhibitor of PDE4 for inhaled administration.
Chapman RW; House A; Richard J; Prelusky D; Lamca J; Wang P; Lundell D; Wu P; Ting PC; Lee JF; Aslanian R; Phillips JE
Eur J Pharmacol; 2010 Sep; 643(2-3):274-81. PubMed ID: 20621091
[TBL] [Abstract][Full Text] [Related]
11. Thiophene inhibitors of PDE4: crystal structures show a second binding mode at the catalytic domain of PDE4D2.
Nankervis JL; Feil SC; Hancock NC; Zheng Z; Ng HL; Morton CJ; Holien JK; Ho PW; Frazzetto MM; Jennings IG; Manallack DT; Martin TJ; Thompson PE; Parker MW
Bioorg Med Chem Lett; 2011 Dec; 21(23):7089-93. PubMed ID: 22030030
[TBL] [Abstract][Full Text] [Related]
12. C-C bond formation at C-2 of a quinoline ring: synthesis of 2-(1H-indol-3-yl)quinoline-3-carbonitrile derivatives as a new class of PDE4 inhibitors.
Kumar KS; Kiran Kumar S; Yogi Sreenivas B; Gorja DR; Kapavarapu R; Rambabu D; Rama Krishna G; Reddy CM; Basaveswara Rao MV; Parsa KV; Pal M
Bioorg Med Chem; 2012 Apr; 20(7):2199-207. PubMed ID: 22386978
[TBL] [Abstract][Full Text] [Related]
13. Quinolines as a novel structural class of potent and selective PDE4 inhibitors: optimisation for oral administration.
Lunniss CJ; Cooper AW; Eldred CD; Kranz M; Lindvall M; Lucas FS; Neu M; Preston AG; Ranshaw LE; Redgrave AJ; Ed Robinson J; Shipley TJ; Solanke YE; Somers DO; Wiseman JO
Bioorg Med Chem Lett; 2009 Mar; 19(5):1380-5. PubMed ID: 19195882
[TBL] [Abstract][Full Text] [Related]
14. Construction of a six-membered fused N-heterocyclic ring via a new 3-component reaction: synthesis of (pyrazolo)pyrimidines/pyridines.
Kumar PM; Kumar KS; Mohakhud PK; Mukkanti K; Kapavarapu R; Parsa KV; Pal M
Chem Commun (Camb); 2012 Jan; 48(3):431-3. PubMed ID: 22075973
[TBL] [Abstract][Full Text] [Related]
15. Novel quinazolin-4(3H)-one/Schiff base hybrids as antiproliferative and phosphodiesterase 4 inhibitors: design, synthesis, and docking studies.
Abdel-Rahman HM; Abdel-Aziz M; Canzoneri JC; Gary BD; Piazza GA
Arch Pharm (Weinheim); 2014 Sep; 347(9):650-7. PubMed ID: 24985336
[TBL] [Abstract][Full Text] [Related]
16. Diastereoselective synthesis and profiling of bicyclic imidazolidinone derivatives bearing a difluoromethylated catechol unit as potent phosphodiesterase 4 inhibitors.
Dorokhov VS; Golovanov IS; Tartakovsky VA; Sukhorukov AY; Ioffe SL
Org Biomol Chem; 2018 Oct; 16(38):6900-6908. PubMed ID: 30024008
[TBL] [Abstract][Full Text] [Related]
17. Novel anilide and benzylamide derivatives of arylpiperazinylalkanoic acids as 5-HT
Jankowska A; Satała G; Kołaczkowski M; Bucki A; Głuch-Lutwin M; Świerczek A; Pociecha K; Partyka A; Jastrzębska-Więsek M; Lubelska A; Latacz G; Gawalska A; Bojarski AJ; Wyska E; Chłoń-Rzepa G
Eur J Med Chem; 2020 Sep; 201():112437. PubMed ID: 32673902
[TBL] [Abstract][Full Text] [Related]
18. Discovery of triazines as selective PDE4B versus PDE4D inhibitors.
Hagen TJ; Mo X; Burgin AB; Fox D; Zhang Z; Gurney ME
Bioorg Med Chem Lett; 2014 Aug; 24(16):4031-4. PubMed ID: 24998378
[TBL] [Abstract][Full Text] [Related]
19. Discovery and Optimization of Thiazolidinyl and Pyrrolidinyl Derivatives as Inhaled PDE4 Inhibitors for Respiratory Diseases.
Carzaniga L; Amari G; Rizzi A; Capaldi C; De Fanti R; Ghidini E; Villetti G; Carnini C; Moretto N; Facchinetti F; Caruso P; Marchini G; Battipaglia L; Patacchini R; Cenacchi V; Volta R; Amadei F; Pappani A; Capacchi S; Bagnacani V; Delcanale M; Puccini P; Catinella S; Civelli M; Armani E
J Med Chem; 2017 Dec; 60(24):10026-10046. PubMed ID: 29200281
[TBL] [Abstract][Full Text] [Related]
20. Discovery and Optimization of α-Mangostin Derivatives as Novel PDE4 Inhibitors for the Treatment of Vascular Dementia.
Liang J; Huang YY; Zhou Q; Gao Y; Li Z; Wu D; Yu S; Guo L; Chen Z; Huang L; Liang SH; He X; Wu R; Luo HB
J Med Chem; 2020 Mar; 63(6):3370-3380. PubMed ID: 32115956
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
